Starling Oncology, Inc. (STLN) vs Zevra Therapeutics, Inc. (ZVRA)

A side-by-side comparison of Starling Oncology, Inc. and Zevra Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Starling Oncology, Inc. logo
STLN
Starling Oncology, Inc.
$658M
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Zevra Therapeutics, Inc. logo
ZVRA
Zevra Therapeutics, Inc.
$634M
$10.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — STLN vs ZVRA

growth of $100 · dividends reinvested · last 1y
STLN +8.6% (+8.6%/yr)ZVRA -23.4% (-23.4%/yr)STLN compounded faster over this window
80100120Start $100$109$77
STLN ZVRA

STLN vs ZVRA: by the numbers

  • •STLN is the larger company ($658M vs $634M market cap).
  • •ZVRA is profitable (42.82% net margin) while STLN runs a net loss (-6.18%).

Metrics side by side

Valuation

MetricSTLNZVRA
P/E ratioN/A11.53
Forward P/EN/A9.68
P/S ratio1.124.66
P/B ratioN/A2.91
EV / EBITDAN/A12.11
FCF yieldN/A5.13%

Profitability

MetricSTLNZVRA
Gross margin15.69%84.52%
Operating margin-4.44%-3.98%
Net margin-6.18%42.82%
ROEN/A26.77%
ROIC-31.32%12.93%

Growth (annualized)

MetricSTLNZVRA
Revenue CAGR (5Y)N/A36.81%
Total return CAGR (5Y)N/A3.75%

Frequently asked

Is STLN or ZVRA more profitable?
ZVRA runs the higher net margin — STLN at -6.18% versus ZVRA at 42.82%.

Go deeper

Full STLN analysisFull ZVRA analysisInteractive comparison tool

Dig into the metrics

Zevra Therapeutics P/E ratioStarling Oncology ROEZevra Therapeutics ROEStarling Oncology operating marginZevra Therapeutics operating marginStarling Oncology revenue growthZevra Therapeutics revenue growthStarling Oncology free cash flowZevra Therapeutics free cash flow

Starling Oncology & Zevra Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.